Levels of Visfatin/NAMPT in Human Milk
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPaolo Manzoni Study Group
About this trial
Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities
Maternal hospitalization
Acquisition of the informed consent form signed by the patient
Disqualifiers
Refusal of the patient to participate in the study
Presence of hypogalactia or agalactia in the patient
Trial population
30 women, hospitalized after childbirth, with respective healthy, breastfed infants
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
observational study
Other interventionobservational study
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Visfatin levels
Visfatin levels in maternal milk samples
Time frame
48 hours, 7 days and 30 days2
Visfatin levels
Visfatin levels in maternal plasma/serum
Time frame
1-2 days post-partumSecondary outcomes
1
values of Visfatin
correlate the values of Visfatin to different demographic and clinical characteristics of the lactating mothers
Time frame
6 months2
values of Visfatin
correlate the values of Visfatin to different biological/clinical features of the newborns; in particular, we will focus attention on the weight loss of the neonate
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Paolo Manzoni Study Group
Lead sponsor
Paolo Manzoni
Sponsor institution
Università degli Studi del Piemonte Orientale Amedeo Avogadro
Collaborator
Source ClinicalTrials.gov